Triple-negative breast cancer (TNBC) is immunohistochemically characterized by lacking gene amplified human epidermal growth factor receptor 2 (HER2), estrogen receptors (ER), and progesterone receptors (PR). This evidence concerns the gene PGR and triple-negative breast carcinoma.